Interpreting the Report
Looking at Ms. Zaveriya Ansari's CBC (14/08/2026):
| Parameter | Result | Reference | Flag |
|---|
| Hemoglobin | 11.0 gm% | 12-16 | Low (mild anemia) |
| RBC count | 5.36 M/cumm | 4-5.2 | High-normal |
| MCV | 64.6 fl | 80-100 | Markedly low (microcytic) |
| MCH | 20.5 pg | 26-34 | Low (hypochromic) |
| MCHC | 31.8 g/dl | 32-36 | Borderline low |
| RDW-CV | 14.6% | 11-16 | Normal |
| Platelets/WBC/differential | normal | | |
| Random blood sugar | 105 mg/dl | 70-140 | Normal |
This is a mild microcytic hypochromic anemia, but the pattern is telling: the RBC count is normal-to-high (not low, as you'd expect with straightforward iron deficiency), and the RDW is normal (cells are uniformly small rather than showing the mixed size variation typical of iron deficiency).
Using the Mentzer index (MCV/RBC) = 64.6/5.36 ≈ 12 - an index below 13 with a normal RDW points toward beta-thalassemia trait (thalassemia minor) rather than classic iron-deficiency anemia, per standard hematology teaching (Harriet Lane Handbook; Quick Compendium of Clinical Pathology - Mentzer index <13 favors thalassemia trait, >13-15 favors IDA).
This is not a definitive diagnosis from a CBC alone. To confirm, she needs:
- Iron studies (serum iron, ferritin, TIBC) - to rule out coexisting iron deficiency
- Hemoglobin electrophoresis / HbA2-HbA2 quantification (HPLC) - to confirm/exclude thalassemia trait
- If confirmed, partner screening is advisable before pregnancy planning, since two thalassemia-trait carriers having children carries risk of thalassemia major in offspring.
Random blood sugar (105 mg/dl) and WBC/platelet counts are all normal - no diabetes or infective/hematologic red flags there.
Blepharitis - Treatment
Blepharitis is chronic eyelid-margin inflammation (staphylococcal and/or seborrheic/meibomian gland dysfunction type), presenting with itching, burning, crusting/collarettes at the lash base, and red, thickened lid margins. It is a chronic, relapsing condition - treatment controls it rather than "cures" it. Standard stepwise management (Wills Eye Manual, Kanski's Ophthalmology):
-
Eyelid hygiene (foundation of treatment)
- Warm compresses 5-10 minutes, twice to four times daily, to soften debris/oil and open meibomian glands
- Followed by gentle lid margin scrubs twice daily with a commercial lid scrub or diluted baby shampoo on a cotton bud/washcloth
-
If dry eye component present: preservative-free artificial tears, 4-8 times/day
-
If moderate severity: erythromycin ointment or azithromycin gel-drops applied to lid margins at bedtime
-
Adjuncts for meibomian gland dysfunction: oral omega-3 fatty acid supplementation; topical cyclosporine (0.05% or 0.09%) or lifitegrast 5% twice daily
-
Unresponsive meibomitis:
- Short course topical antibiotic-steroid combination (e.g., tobramycin/dexamethasone) 2-3 times/day
- Oral doxycycline 100 mg once daily for 1-2 weeks, then tapered and maintained at low dose for 3-6 months (anti-inflammatory effect on meibomian secretions)
- Alternative: azithromycin 500 mg/day for 3 days, repeated for 3 cycles with 7-day gaps
- Doxycycline should not be used in pregnancy, breastfeeding, or children ≤8 years - substitute erythromycin 200 mg twice daily in those situations
-
If Demodex mite involvement suspected (look for cylindrical collarettes on lashes): tea-tree oil lid scrubs or a hypochlorous-acid lid cleanser once/twice daily for at least 6 weeks
-
Refractory cases: in-office meibomian gland thermal expression, intense pulsed light therapy, microblepharoexfoliation, or gland probing
Follow-up is typically at 2-4 weeks; once controlled, hygiene frequency can often be reduced to once daily but usually needs to continue indefinitely to prevent recurrence.
A note on the two findings together: there is no established causal link between mild thalassemia-trait anemia and blepharitis - these are separate, unrelated conditions in her case. Treat them independently: hematology work-up (iron studies + Hb electrophoresis) for the anemia, and lid hygiene/topical therapy as above for the blepharitis.
Recent evidence check: A 2025 Cochrane systematic review on topical immunosuppressants (cyclosporine/tacrolimus) for adult blepharitis (PMID: 41263273) and a 2024 meta-analysis on lotilaner 0.25% for Demodex blepharitis (PMID: 38301215) support the above regimen but note that evidence quality for many blepharitis treatments remains limited - reinforcing that lid hygiene remains first-line, with pharmacologic escalation reserved for non-responders.
I'm not a substitute for her treating ophthalmologist/physician (Dr. Qasim Chimthawala) - please have him confirm the anemia work-up plan and tailor the blepharitis regimen to her exam findings (Demodex, rosacea, meibomian gland status).